FI971750A - Koostumuksia multippeliskleroosia varten ja sen hoito - Google Patents

Koostumuksia multippeliskleroosia varten ja sen hoito Download PDF

Info

Publication number
FI971750A
FI971750A FI971750A FI971750A FI971750A FI 971750 A FI971750 A FI 971750A FI 971750 A FI971750 A FI 971750A FI 971750 A FI971750 A FI 971750A FI 971750 A FI971750 A FI 971750A
Authority
FI
Finland
Prior art keywords
compositions
treatment
multiple sclerosis
sclerosis
Prior art date
Application number
FI971750A
Other languages
English (en)
Swedish (sv)
Other versions
FI971750A0 (fi
Inventor
Dawn Smilek
Michael Samson
Malcolm Gefter
Di-Hwei Hsu
Jia-Dong Shi
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of FI971750A0 publication Critical patent/FI971750A0/fi
Publication of FI971750A publication Critical patent/FI971750A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI971750A 1994-10-25 1997-04-24 Koostumuksia multippeliskleroosia varten ja sen hoito FI971750A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15
PCT/US1995/013682 WO1996012737A2 (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis

Publications (2)

Publication Number Publication Date
FI971750A0 FI971750A0 (fi) 1997-04-24
FI971750A true FI971750A (fi) 1997-06-24

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971750A FI971750A (fi) 1994-10-25 1997-04-24 Koostumuksia multippeliskleroosia varten ja sen hoito

Country Status (15)

Country Link
EP (1) EP0787147A1 (fi)
JP (1) JPH10504039A (fi)
AU (1) AU4278296A (fi)
BR (1) BR9509438A (fi)
CA (1) CA2203629A1 (fi)
CZ (1) CZ122697A3 (fi)
FI (1) FI971750A (fi)
HU (1) HUT77047A (fi)
IL (1) IL115766A0 (fi)
IS (1) IS4466A (fi)
NO (1) NO971900L (fi)
PL (1) PL324091A1 (fi)
SI (1) SI9520118A (fi)
SK (1) SK51297A3 (fi)
WO (1) WO1996012737A2 (fi)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) * 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
GB2349463B (en) 1996-03-21 2001-01-10 Circassia Ltd Cryptic peptides and method for their identification
CA2263730A1 (en) * 1996-08-15 1998-02-19 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2494338C (en) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
CN1308671A (zh) * 1998-05-05 2001-08-15 科里克萨公司 髓磷脂碱性蛋白肽及其应用
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO1999060021A2 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
ATE431410T1 (de) 2002-03-27 2009-05-15 Aegera Therapeutics Inc Gegen iap gerichtete antisense-nukleobasen und deren verwendungen
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
US8920808B2 (en) 2006-10-31 2014-12-30 East Carolina University Cytokine-based fusion proteins for treatment of multiple sclerosis
US8815794B2 (en) * 2008-08-28 2014-08-26 The Research Foundation For The State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
EP3348275A3 (en) * 2009-03-31 2018-10-24 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
EP2488196B1 (en) 2009-10-12 2015-12-16 LIFEBio Laboratories LLC Composition for treatment of multiple sclerosis
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
CA2830772C (en) 2011-03-21 2020-04-28 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
JP6629234B2 (ja) 2014-01-13 2020-01-15 バーグ エルエルシー エノラーゼ１（ｅｎｏ１）組成物及びその使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336954C (en) * 1987-06-24 1995-09-12 Howard L. Weiner Treatment of autoimmune diseases by oral administration of autoantigens
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
DE69033487T2 (de) * 1989-12-20 2000-06-29 Autoimmune, Inc. Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
WO1991012816A1 (en) * 1990-03-02 1991-09-05 Autoimmune, Inc. Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
WO1993009810A1 (en) * 1991-11-19 1993-05-27 Anergen, Inc. Mhc subunit conjugates useful in ameliorating deleterious immune responses
WO1993016724A1 (en) * 1992-02-28 1993-09-02 Autoimmune, Inc. Bystander suppression of autoimmune diseases
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
EP0650498B1 (en) * 1992-04-09 1998-09-09 Autoimmune, Inc. Suppression of t-cell proliferation using peptide fragments of myelin basic protein
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
IL106720A (en) * 1992-08-17 1998-10-30 Autoimmune Inc The use of antigen bystander in the preparation of compositions for the treatment of neurologically related diseases in mammals and such compositions
WO1995006727A2 (en) * 1993-09-03 1995-03-09 Immulogic Pharmaceutical Corporation Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
WO1995008572A1 (en) * 1993-09-22 1995-03-30 The Board Of Trustees For The Leland Stanford Junior University Interaction of t-cell receptors and antigen in autoimmune disease
BR9507452A (pt) * 1994-04-08 1997-08-05 Brigham & Womens Hospital Composição farmacêutica uso de um polipeptídeo não-interferon uso de uma quantidade de um antígeno padronizado e uma quantidade de um polipeptídeo não-interferon e produto contendo (1) uma quantidade de um antígeno padronizado e (11) uma quantidade de um polipeptídeo não-interferon
JPH09511745A (ja) * 1994-04-08 1997-11-25 ブリガム アンド ウィミンズ ホスピタル 経口寛容および／またはタイプｉインターフェロンを用いた自己免疫疾患の治療
HUT76099A (en) * 1994-05-10 1997-06-30 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis
CA2192468A1 (en) * 1994-06-09 1995-12-14 Johannes M. Van Noort Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
ATE213499T1 (de) * 1994-11-18 2002-03-15 Neurocrine Biosciences Inc Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein

Also Published As

Publication number Publication date
HUT77047A (hu) 1998-03-02
NO971900L (no) 1997-06-25
CA2203629A1 (en) 1996-05-02
WO1996012737A2 (en) 1996-05-02
BR9509438A (pt) 1997-12-23
JPH10504039A (ja) 1998-04-14
IS4466A (is) 1997-04-17
SK51297A3 (en) 1998-03-04
SI9520118A (sl) 1998-08-31
FI971750A0 (fi) 1997-04-24
PL324091A1 (en) 1998-05-11
NO971900D0 (no) 1997-04-24
IL115766A0 (en) 1996-01-19
WO1996012737A3 (en) 1996-10-10
CZ122697A3 (en) 1997-09-17
AU4278296A (en) 1996-05-15
EP0787147A1 (en) 1997-08-06

Similar Documents

Publication Publication Date Title
FI971750A0 (fi) Koostumuksia multippeliskleroosia varten ja sen hoito
FI971969A (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
FI970563A (fi) Parannettu puhdistuskoostumus
FI955980A (fi) Menetelmä ja laite uudelleenjärjestämiseen
DE69513916D1 (de) Oberflächenbehandlungszusammensetzung
FI964330A (fi) Menetelmä ja laite porrashissejä varten
FI960483A0 (fi) Muunnettava koostumus ja menetelmät sen käyttämiseksi
FI962976A0 (fi) Viherkaihin hoitoon tarkoitettuja koostumuksia, jotka sisältävät beta-salpaajaa
DE69527272D1 (de) Reinigungszusammensetzung
FI972306A (fi) Substituoituja 2-aryylikarbonyylioksimetyyli-1,2,5-tiadiatsolidin -3- oni-1,1-dioksidi-johdannaisia ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
HU9603116D0 (en) Compositions and treatment for multiple sclerosis
FI971138A0 (fi) Keraamisia eristeitä ja menetelmiä niiden muodostamiseksi
FI971376A0 (fi) Trofinin och trofininmedlande proteiner
DE69527268D1 (de) Reiningungszusammensetzung
FI91347C (fi) Menetelmä aikavälikytkennän suorittamiseksi sekä aikakytkin
FI972307A (fi) 2-(2,3,5,6-tetrafluori-4-pyridyyli)-1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
SE9400371L (sv) Kompositioner för inhalation
FI952030A0 (fi) Smaeltprocessbar polyesteruretan och foerfarande foer framstaellning daerav
SE9403758D0 (sv) Arrangemang för rengöring
SE9402744D0 (sv) Komposition för permanentning av hår
SE9200329D0 (sv) Alldisk och allrengoeringsmedel
FI1506U1 (fi) Braennbart uppvaermningsredskap foer bruk utomhus och i eldstaeder
SE9400370L (sv) Terapeutisk komposition för inhalation
ZA953730B (en) Compositions and treatment for multiple sclerosis
FI944377A0 (fi) Foerfarande och anordning foer saogning med en aendloes bandsaog